Cell and gene therapies offer hope to many individuals for which current treatments have proven unsuccessful.
SAN FRANCISCO (PRWEB) December 16, 2022
American Pharmaceutical Review, the leading review of business and technology for the pharmaceutical industry throughout North America and Pharmaceutical Outsourcing magazine a journal dedicated to pharmaceutical and biopharmaceutical contract services that provides the most complete coverage of trends and issues in the industry have released their documentary on “Cell and Gene Therapy: Advancing the Next Generation of Pharmaceuticals”. The goal of the documentary is to examine how cell and gene therapies, which fall into the broader category of drugs known as Advanced Therapy Medicinal Products (ATMPs) have emerged as an incredibly promising class of treatments that have shown the ability to treat and even cure many individuals with diseases for which there was little to no hope.
The documentary features commentary and outlook from key opinion leaders representing regulatory, industry, and technology providers who offer their thoughts and outlook on the current state of cell and gene therapy development, manufacturing, and distribution.
"Cell and gene therapies offer hope to many individuals for which current treatments have proven unsuccessful. But, as with most cutting-edge technologies there are many issues to sort out.” says Mike Auerbach, Editor in Chief, American Pharmaceutical Review and Pharmaceutical Outsourcing. “In this video documentary we explore where the industry is in terms of developing cell and gene therapies, current and future technologies, and what the regulatory environment is for these promising treatments.”
The market outlook for cell and gene therapies is expected to grow in the coming years. According to Research and Markets report " Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027”, the cell and gene therapy market size was valued at USD 4.99 billion in 2021 and is expected to reach USD 36.92 billion by 2027, growing at a CAGR of 39.62 % during the forecast period. The report goes on to mention that “Increasing application of gene therapies in diseases diagnosis and rapidly growing new drugs applications will give new market space in upcoming years. In 2020, around USD 2.3 billion funding was reported only from private companies for gene therapies. By 2025, the FDA is expected to approve 10−20 products each year, driving the global cell and gene therapy manufacturing market.”
For more information on this documentary on Cell and Gene Therapy: Advancing the Next Generation of Pharmaceuticals please visit: https://www.americanpharmaceuticalreview.com/Cell-and-Gene-Therapy/.
About American Pharmaceutical Review
American Pharmaceutical Review is the leading journal for business and technology in the pharmaceutical industry. Offering unbiased editorial on drug delivery, information technology, research & development, analytical development and control, equipment and facility manufacturing and regulatory affairs, American Pharmaceutical Review keeps its users fully abreast of the latest trends and developments in the process of pharmaceutical manufacturing. http://www.americanpharmaceuticalreview.com
About Pharmaceutical Outsourcing
Pharmaceutical Outsourcing is a journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs and other areas, Pharmaceutical Outsourcing provides the most complete coverage of trends and issues in the industry.